Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of antigen escape. The most widely used approaches include CD19/CD20, CD20/CD22, and BCMA/CD19 CAR T-cells. Alternative immune cells, including natural killer T cells and invariant natural killer T cells, exhibit innate anti-tumor activity and reduced toxicity. This review summarizes several recent clinical trial reports and preclinical studies from the 2023 American Society of Hematology (ASH) annual meeting on dual-targeted CAR T-cell immunotherapy for hematological malignancies.

中文翻译：

---

血液恶性肿瘤双靶点CAR T细胞免疫疗法：2023年ASH年会最新动态

在过去的几年中，双靶点嵌合抗原受体（CAR）T 细胞疗法已被用于治疗血液恶性肿瘤，以减少治疗失败，特别是在抗原逃逸的情况下。最广泛使用的方法包括 CD19/CD20、CD20/CD22 和 BCMA/CD19 CAR T 细胞。替代免疫细胞，包括自然杀伤 T 细胞和不变自然杀伤 T 细胞，表现出先天的抗肿瘤活性和较低的毒性。本综述总结了 2023 年美国血液学会 (ASH) 年会的几项近期关于双靶向 CAR T 细胞免疫治疗血液恶性肿瘤的临床试验报告和临床前研究。